Finder makes money from featured partners, but editorial opinions are our own.

How to buy Medtronic (MDT) shares in Australia

Learn how to easily invest in Medtronic shares.

Medtronic PLC (MDT) is a leading medical devices business with stocks listed in the US. It opened the day at US$78.9 after a previous close of US$79. During the day the price has varied from a low of USD78.4 to a high of USD79.05. The latest price was USD78.86 (25 minute delay). Medtronic is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Medtronic

  1. Compare share trading platforms. To buy shares in a company listed in the US from Australia you'll need to find a trading platform that offers access to US stock markets. Look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, which will typically include your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Medtronic. Find the share by name or ticker symbol: MDT. Research its history to confirm it's a solid investment that matches your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Medtronic reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying using consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$79, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Medtronic, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Medtronic. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights.

Medtronic stock price (NYSE:MDT)

Use our graph to track the performance of MDT stocks over time.

Have Medtronic's shares ever split?

Medtronic's shares were split on a 2:1 basis on 27 September 1999. So if you had owned 1 share the day before the split, the next day you would own 2 shares. This wouldn't directly have changed the overall worth of your Medtronic shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Medtronic shares which in turn could have impacted Medtronic's share price.

Medtronic shares at a glance

Information last updated 2023-11-28.
OpenUS$78.9
HighUS$79.05
LowUS$78.4
CloseUS$78.86
Previous closeUS$79
Change US$-0.14
Change % -0.1772%
Volume 3,033,048
Information last updated 2023-11-26.
52-week rangeUS$68.84 - US$90.5279
50-day moving average US$74.9124
200-day moving average US$81.9821
Target priceUS$90.15
PE ratio 25.6396
Dividend yield US$2.74 (3.49%)
Earnings per share (TTM) US$3.08

Medtronic share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Medtronic price performance over time

Historical closes compared with the last close of $78.86

1 week (2023-11-21) 0.31%
1 month (2023-10-27) 13.58%
3 months (2023-08-28) -3.11%
6 months (2023-05-26) -3.19%
1 year (2022-11-28) 3.59%
2 years (2021-11-26) -28.99%
3 years (2020-11-27) -31.18%
5 years (2018-11-28) -17.31%

Compare trading platforms to buy Medtronic shares

1 - 6 of 6
Name Product Standard brokerage for US shares Currency conversion fee Asset class
eToro
Finder AwardExclusive
eToro
US$0
50-150 pips
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
US$0
0.70%
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
US$1.99
55 pips or 0.0055 AUD/USD
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts (see link for details). T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 18 million investors.
CMC Markets Invest
Finder Award
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
Special offer: Transfer your international stocks to CMC Invest and receive $100 credit on your trading account until Nov 30, 2023 (T&Cs apply).
Trade up to 35,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
Webull
US$0.25
0.50% (50 pips)
ASX shares, Options trading, US shares, ETFs
Fund your new account with $500 and place 1 trade to get $100 in free rewards until November 30, 2023. Plus, earn up to 5.2% p.a. interest on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Exclusive
Tiger Brokers
US$2
37 pips
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 15 commission-free trades on US or ASX equities for the first 180 days plus US$50 fractional shares when you deposit at least $500 within the first 7 days of account opening. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.
loading
The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Medtronic stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Is Medtronic under- or over-valued?

Valuing Medtronic stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medtronic's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medtronic's P/E ratio

Medtronic's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 26x. In other words, Medtronic shares trade at around 26x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Medtronic's PEG ratio

Medtronic's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.0399. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medtronic's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medtronic's EBITDA

Medtronic's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$8.7 billion (£6.8 billion).

The EBITDA is a measure of a Medtronic's overall financial performance and is widely used to measure a its profitability.

Medtronic share price volatility

Over the last 12 months, Medtronic's shares have ranged in value from as little as US$68.84 up to US$90.5279. A popular way to gauge a stock's volatility is its "beta".

MDT.US volatility(beta: 0.72)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Medtronic's is 0.722. This would suggest that Medtronic's shares are less volatile than average (for this exchange).

Medtronic financials

Revenue TTM US$32 billion
Operating margin TTM 20.77%
Gross profit TTM US$21.7 billion
Return on assets TTM 4.23%
Return on equity TTM 7.96%
Profit margin 12.84%
Book value 38.687
Market capitalisation US$105.1 billion

TTM: trailing 12 months

Medtronic share dividends

41%

Dividend payout ratio: 41.39% of net profits

Recently Medtronic has paid out, on average, around 41.39% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.49% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Medtronic shareholders could enjoy a 3.49% return on their shares, in the form of dividend payments. In Medtronic's case, that would currently equate to about $2.74 per share.

While Medtronic's payout ratio might seem fairly standard, it's worth remembering that Medtronic may be investing much of the rest of its net profits in future growth.

Medtronic's most recent dividend payout was on 13 October 2023. The latest dividend was paid out to all shareholders who bought their shares by 21 September 2023 (the "ex-dividend date").

Medtronic's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Medtronic.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Medtronic's total ESG risk score

Total ESG risk: 26.86

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Medtronic's overall score of 26.86 (as at 01/01/2019) is nothing to write home about – landing it in it in the 41st percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Medtronic is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Medtronic's environmental score

Environmental score: 4.07/100

Medtronic's environmental score of 4.07 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Medtronic's social score

Social score: 15.28/100

Medtronic's social score of 15.28 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that Medtronic is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Medtronic's governance score

Governance score: 9/100

Medtronic's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that Medtronic is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Medtronic's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Medtronic scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Medtronic hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Medtronic PLC was last rated for ESG on: 2019-01-01.

Total ESG score 26.86
Total ESG percentile 40.62
Environmental score 4.07
Environmental score percentile 5
Social score 15.28
Social score percentile 5
Governance score 9
Governance score percentile 5
Level of controversy 3

Medtronic overview

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site